MedPath

Comparing three different dosages of drugs in adult patients planned for General Anaesthesia

Phase 1
Not yet recruiting
Conditions
NIL
Registration Number
CTRI/2017/11/010415
Lead Sponsor
Ms Meena
Brief Summary

1. To compare rocuronium with two different doses with succinylcholine with regard to onset of intubating condition in adult patients for elective surgeries.

2. Rocuronium 0.9mg/kg body weight takes 60 sec for intubating conditions wit prolonged actions where as succinylcholine 2mg/kg bodyweight takes 45sec for intubating conditions.

Low dose of rocuronium 0.6mg/kg body weight has chosen as it is associated with shorter duration of action. The aim is to find out wether the low dose itself is sufficient to the procedure for intubating conditions.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
105
Inclusion Criteria
  • American society of Anesthesiologist Category 1 and 2 Controlled hypertension & Controlled Diabetic with Controlled haemoglobin with Mallamapati grade 1 & 2 for mouth opening.
  • Cormack-Lehane grading 1 and 2.
Exclusion Criteria
  • Hyperkaelemia 2.
  • Uncontrolled Hypertension 3.
  • Uncontrolled Diabetes 4.
  • Neurological Problems 5.
  • Difficult Airway.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare two doses of rocuronium with succinylcholine with regard to onset of endotracheal intubation in adult patients for elective surgeries1. Onset of endotracheal Intubation | 2. Intubating condition
Secondary Outcome Measures
NameTimeMethod
To compare two doses of rocuronium with suuinylcholine with regard to time taken to intubate and duration of actionTime taken to intubate

Trial Locations

Locations (1)

Department Of Anaesthesia

🇮🇳

Chennai, TAMIL NADU, India

Department Of Anaesthesia
🇮🇳Chennai, TAMIL NADU, India
Henry Prabhu Alfred
Principal investigator
9884681395
henryalfred23@hotmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.